This collaboration is also aimed at expediting early-phase clinical trials and delivering new therapies to patients. It will leverage both organisations’ expertise to advance healthcare innovation. Each partner
The agreement grants Sanofi worldwide rights to KT501, which is under evaluation in a first-in-human clinical trial for rheumatoid arthritis, focusing on tolerability, safety, pharmacodynamics, and pharmacokinetics. Under
This approval covers adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) who have carcinoma in situ (CIS), with or without papillary tumours. The authorisation follows a review
The FDA has approved Opdivo, along with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and paediatric patients aged 12 years and above who have not previously been treated
Under the contract, Novartis will pay $2bn upfront and up to $1bn in milestones to acquire Synnovation Therapeutics’ wholly owned subsidiary Pikavation Therapeutics, which holds SNV4818 and related
The portfolio includes programmes targeting melanocortin 4 receptor (MC4R)-deficient genetic obesity, glucocerebrosidase 1 (GBA1)-driven Parkinson’s disease, and Alpha-1 antitrypsin deficiency. The financing was co-led by Dimension and OrbiMed,
The company also secured an exclusive global licence for the development and commercialisation of AP306 with Alebund Pharmaceuticals, excluding Greater China. The funding will support the global development
This CRL stated that the application lacks substantial evidence of efficacy from adequate and well-controlled clinical investigations under the proposed conditions of use. The FDA noted inconsistencies in
The regulatory action date for the humanised immunoglobulin G1, kappa (IgG1/k) monoclonal antibody sBLA review is anticipated by 29 October 2026. If approved, this would expand the therapy’s
The move enables Sentynl to collaborate immediately with PRG S&T to advance clinical development of the molecule, which holds orphan drug status from the US Food and Drug
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.